Guide
The National Medical Insurance Administration has decided to formally implement the new version of the catalog from March 1, 2021.
Source: Medical Naomaitong
Author: This article through small veins
consolidate edited by the Medical vein, do not be reproduced without authorization.
On the morning of December 28, the National Medical Insurance Bureau held a press conference for the 2020 medical insurance drug catalog in Beijing, and released the latest version of the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2020" (hereinafter referred to as the "2020 Drug Catalog" ").
This year, the National Medical Insurance Bureau negotiated a total of 162 kinds of drugs. The negotiation succeeded in 119 kinds (including 96 out of the catalog and 23 in the catalog), the success rate was 73.46%, and the average price was reduced by 50.64%. The catalogue adjusted this time. Newly transferred 119 kinds of drugs (including 96 kinds of exclusive drugs and 23 kinds of non-exclusive drugs).
Source: CCTV News
After this catalog adjustment, 119 kinds of medicines were transferred into the catalog, 29 kinds of medicines were transferred out of the catalog, and finally There are a total of 2,800 drugs in the adjusted "Drug Catalogue 2020", of which 1,426 are Western medicines and 1,374 are proprietary Chinese medicines. The proportion of Chinese and Western medicines is basically the same.
What are the differences and highlights of this medical insurance catalog adjustment compared with the past?
1. Implementation of the declaration system
According to the interpretation information of the "2020 Drug Catalog" issued by the National Medical Insurance Administration, it is different from the previous rounds of adjustments that included "all listed drugs" in the review scope. The declaration system is implemented for the first time this year, which is in line with this year's adjustments. Only drugs out of the list under the conditions listed in the plan can be included in the scope of adjustment. The adjustment range of drugs out of the list has realized the transition from "sea selection" to "preferred".
2. The most price cuts have been adjusted, and the treatment field is the widest.
compared with previous years In comparison, an important feature of this adjustment is that the number of medicines negotiated for price reductions is the largest, and the treatment fields benefited the most.
This time, the National Medical Insurance Bureau negotiated a total of 162 medicines, and the negotiations were successful 119 (including 96 out of the catalog). There are 23 kinds of drugs in the catalog), the success rate is 73.46%, and the average price reduction of is 50.64%. The adjustment of 's catalogue includes a total of 119 new drugs (including 96 exclusive drugs and 23 non-exclusive drugs). These drugs involve a total of 31 Z5z accounted for 86% of all clinical groups. patients benefit from a wide range of patients, and the patient’s sense of gain will be more intense.
3. All drugs for the treatment of new coronary pneumonia are included in the medical insurance list
. This adjustment is to attach great importance to the treatment of new coronary pneumonia. For the protection of related drugs, ribavirin injection, Arbidol granules and other drugs have been added to the catalog. The drugs listed in the latest version of the National New Coronary Pneumonia Diagnosis and Treatment Program have all been included in the National Medical Insurance Catalog, and actual actions are taken to help prevent and control the epidemic Z1z
is included in the adjusted non-catalog drugs, what are the considerations?
According to the "2020 National Medical Insurance Drug Catalog Adjustment Work Plan", there are mainly 7 types of non-catalog drugs adjusted this year:
1. Drugs for the treatment of respiratory diseases related to new coronary pneumonia ; Z1z
2. Drugs included in the "National Essential Drug List (2018 Edition)";
3. Be included in the list of urgently needed overseas new drugs by relevant departments, encourage generic drug lists, or encourage R&D to declare drugs for children's drugs;
4. Included in the scope of national centralized procurement Drugs;
5. Drugs approved for marketing after January 1, 2015;
6. Drugs with major changes in indications, functions and indications after January 1, 2015;
7. Drugs that take into account the original supplementary drugs of each province For continuity, this time, "drugs included in the catalog of 5 or more provincial medical insurance drugs" are also included in the adjustment scope.
According to the application conditions, a total of 704 non-catalog drugs have been successfully declared. The main consideration of
setting the application conditions is:
1. To better meet clinical needs.
For example, drugs used for the treatment of new coronary pneumonia, drugs that are urgently needed in clinical practice or encouraged to be copied, national essential drugs, drugs selected from centralized procurement, etc.
2. Better link up with new drug approval, realizes the "seamless link" of drug approval and medical insurance review, reflecting the encouragement of new drug creationguide.
For example, newly marketed drugs, newly approved drugs with modified functions and indications.
3. Take care of the continuity of clinical medication.
, for example, drugs that are included in 5 or more provincial medical insurance drug lists are also included in the adjustment scope.
Why are 29 drugs removed from the medical insurance catalog?
The interpretation information of the "Drug Catalogue 2020" issued by the National Medical Insurance Administration stated: After expert review, a total of 29 drugs have been removed from the catalogue, mainly because they have low clinical value and can be replaced, or their registration numbers have been revoked by the drug administration and become "zombie" "Medicine" and other varieties. The release of these drugs has been repeatedly verified by experts and determined strictly in accordance with procedures. During the review process, experts regard substitutability as an important indicator, and all drugs with equivalent or better efficacy are available for substitution in the drug catalogs that have been transferred. At the same time, the release of these drugs has made room for more new and good drugs to be included in the catalog.
14 anti-cancer drugs are reduced in price, 17 new anti-cancer drugs are added
According to the National Medical Insurance Administration, in 2018, at the beginning of its establishment, the National Medical Insurance Agency organized special access negotiations for anti-cancer drugs, and finally 17 drugs were successfully included in the catalog. , And the agreement expires at the end of this year. Among these 17 anti-cancer drugs, 3 drugs have generic drugs on the market and are included in Class B management. The 14 exclusive drugs were renewed or negotiated again in accordance with the rules, with an average drop of 14.95%, of which some first-line anticancer drugs dropped by more than 60%. It is estimated that the price of 14 anti-cancer drugs will be reduced, which is expected to save more than 3 billion yuan for cancer patients in 2021.
At the same time, 17 new anticancer drugs have been added in this adjustment, including PD-1, lenvatinib and other new drugs, and the level of protection for cancer drugs in the catalog has been significantly improved. According to the National Medical Insurance Bureau, due to the epidemic, this year's adjustment work did not end until December. In order to reserve time for local medical insurance departments and agencies in terms of system adjustment, policy convergence, and personnel training, the National Medical Insurance Bureau of has decided to formally implement the new version of the catalog from March 1, 2021. Edited by
Xiaomai Su Mu
